Compare CODA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | ENTX |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | CODA | ENTX |
|---|---|---|
| Price | $9.36 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 54.3K | ★ 138.9K |
| Earning Date | 01-28-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | $124,000.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | ★ 29.34 | 25.25 |
| 52 Week Low | $5.76 | $1.50 |
| 52 Week High | $10.54 | $3.22 |
| Indicator | CODA | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 41.80 |
| Support Level | $8.80 | $1.53 |
| Resistance Level | $9.60 | $2.04 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 50.56 | 47.97 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.